Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Aditi Singhai
Alison Sathe
Anders Vinther
Anne-Caroline Boillot
Barbara W. Unger
Barry Price
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Khushboo Agrawal
Mark Agostino
Michael de la Torre
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Tashil Sharma
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.
Conference Spotlight

Preparing for a Virtual FDA Inspection: Advice from Former FDA Investigator and Investigations Director Ricki Chase

No items found.
Enforcement

Warning Letters Week of 07/05/20: Supplier Qualification

No items found.
Conference Spotlight

A State-of-the-Art Virtual Inspection Methodology Using Mixed Reality Technology Gets High Marks from European Medicines Agency Inspector

No items found.
Enforcement

Warning Letters 06/28/20: Unapproved Vendors

No items found.
Conference Spotlight

Yes, FDA is Still Performing Pharma Inspections, Using Risk-Based Criteria: What is Your Risk for Inspection?

No items found.
Enforcement

FDA Warning Letters Week of 06/21/20: For-Cause Inspection & Untitled Letter From A 2018 Inspection

No items found.
Conference Spotlight

Microbiological Issues with Aseptic Processing and Lyophilization: CGMP Inspection Case Study by FDA National Drug Expert Ileana Barreto-Pettit

No items found.
Enforcement

Warning Letters Week of 06/14/20: Data Integrity

No items found.
Conference Spotlight

Inadequate Media Fills at a Sterile Manufacturer When Starting up After a Shutdown: CGMP Inspection Case Study by FDA National Drug Expert Ileana Barreto-Pettit

No items found.
Conference Spotlight

Cleaning and Cross-contamination Issues with an Encapsulator: CGMP Inspection Case Study by FDA National Drug Expert Ileana Barreto-Pettit

No items found.
Conference Spotlight

David Doleski Encourages Industry to Participate in FDA’s Emerging Technology Efforts; Sanofi Case Study Reviewed

No items found.
Trends

What is Risk-Based Thinking?

No items found.
Enforcement

FDA Warning Letters Week of 05/24/20: Sterile Drugs, OTC Products, & Hiring of Quality Consultants

No items found.
Conference Spotlight

Former FDA Official David Doleski on Agency Hot Button Issues and Developing a Positive Relationship

No items found.
Enforcement

Warning Letters Week of 5/17/20

No items found.
Enforcement

Warning Letters Week of 5/3/2020: 42 Concern COVID-19 Claims

No items found.
Conference Spotlight

Avoiding and Reacting to Human Tissue, Cell, and Gene Therapy Enforcement Actions: Communication is Key

No items found.
Enforcement

FDA Warning Letters Week of 4/27/2020: HCT/P

No items found.